Topic Review
The Development Perspective and Recommendations of Biosimilars
Making biosimilars accessible means reducing their cost of development, which is currently at around USD 100–200 million, keeping small and medium-size companies out of play and leaving most current biosimilars in the hands of big pharma. How this cost breaks down is an interesting subject.
  • 462
  • 27 Apr 2022
Topic Review
The Genus Cetraria s. str.
The genus Cetraria s. str. (Parmeliaceae family, Cetrarioid clade) consists of 15 species of mostly erect brown or greenish yellow fruticose or subfoliose thallus. These Cetraria species have a cosmopolitan distribution, being primarily located in the Northern Hemisphere, in North America and in the Eurasia area. 
  • 449
  • 24 Aug 2022
Topic Review
The Genus Porophyllum
The genus Porophyllum (family Asteraceae) is native to the western hemisphere, growing in tropical and subtropical North and South America. Mexico is an important center of diversification of the genus. Plants belong of genus Porophyllum have been used in Mexican traditional medicine to treat kidney and intestinal diseases, parasitic, bacterial, and fungal infections and anti-inflammatory and anti-nociceptive activities.
  • 804
  • 28 Sep 2021
Topic Review
The Labdane Diterpenoid-Andrographolide
The diterpene lactone andrographolide, isolated from Andrographis paniculata (Burm.f.) Wall. ex Nees that showed shows a plethora of biological activities, including not only anti-cancer activity, but also anti-inflammatory, anti-viral, anti-bacterial, neuroprotective, hepatoprotective, hypoglycemic, and immunomodulatory properties. Andrographolide has been shown to act as an anti-tumor drug by affecting specific molecular targets that play a part in the development and progression of several cancer types including breast, lung, colon, renal, and cervical cancer, as well as leukemia and hepatocarcinoma.
  • 822
  • 22 May 2023
Topic Review
The Mechanism-Based Inactivation of CYP3A4 by Ritonavir
Ritonavir is the most potent cytochrome P450 (CYP) 3A4 inhibitor in clinical use and is often applied as a booster for drugs with low oral bioavailability due to CYP3A4-mediated biotransformation, as in the treatment of HIV (e.g., lopinavir/ritonavir) and more recently COVID-19 (Paxlovid or nirmatrelvir/ritonavir). Ritonavir is clearly a potent mechanism-based inactivator, which irreversibly blocks CYP3A4. 
  • 835
  • 19 Sep 2022
Topic Review
The Mechanisms of Clozapine-Induced Neutropenia
Despite its severe adverse effects, such as agranulocytosis, clozapine is the primary treatment for treatment-resistant schizophrenia. Clozapine is the gold standard for treatment-resistant schizophrenia. It was discovered over a half-century ago by researchers at Wander AG, a Swiss pharmaceutical company. After a decade, the use of clozapine began to fade away due to its alarming side effect but was re-introduced in the year 1989 for the treatment of refractory psychosis. Numerous comparative studies between clozapine and other antipsychotics have reported superior efficacy of clozapine in treatment-resistant schizophrenia.
  • 2.1K
  • 10 Nov 2021
Topic Review
The Medicinal Properties for FDA-Approved Oximes
Organophosphate (OP) poisoning continues to be a major threat to humans. Oximes represent the most important class in medicinal chemistry, renowned for their widespread applications as OP antidotes, drugs and intermediates for the synthesis of several pharmacological derivatives. Common oxime based reactivators or nerve antidotes include pralidoxime, obidoxime, HI-6, trimedoxime and methoxime, among which pralidoxime is the only FDA-approved drug. Cephalosporins are β-lactam based antibiotics and serve as widely acclaimed tools in fighting bacterial infections. Oxime based cephalosporins have emerged as an important class of drugs with improved efficacy and a broad spectrum of anti-microbial activity against Gram-positive and Gram-negative pathogens.
  • 1.0K
  • 21 Jan 2022
Topic Review
The Pharmaceutical Industry in 2021
2021 will be remembered for the COVID-19 pandemic. Although five vaccines have been approved by the two most important drug regulatory agencies, namely the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA), the pandemic has still not been brought under control. However, despite the context of a global pandemic, 2021 has been an excellent year with respect to drug approvals by the FDA. In 2021, 50 drugs have been authorized, making it the fourth-best year after 2018 (59 drugs) and 1996 and 2020 (53 each). Regarding biologics, 2021 has been the third-best year to date, with 14 approvals, and it has also witnessed the authorization of 36 small molecules.
  • 693
  • 21 Mar 2022
Topic Review
The Pharmacological Activities of Siraitia grosvenorii 
Siraitia grosvenorii (Swingle) C. Jeffrey ex Lu et Z. Y. Zhang is a unique economic and medicinal plant of Cucurbitaceae in Southern China. For hundreds of years, Chinese people have used the fruit of S. grosvenorii as an excellent natural sweetener and traditional medicine for lung congestion, sore throat, and constipation. It is one of the first species in China to be classified as a medicinal food homology, which has received considerable attention as a natural product with high development potential. Various natural products, such as triterpenoids, flavonoids, amino acids, and lignans, have been released from this plant by previous phytochemical studies. Pharmacological research of the fruits of S. grosvenorii has attracted extensive attention, and an increasing number of extracts and compounds have been demonstrated to have antitussive, expectorant, antiasthmatic, antioxidant, hypoglycemic, immunologic, hepatoprotective, antibacterial, and other activities.
  • 537
  • 04 Nov 2022
Topic Review
The Pharmacological Therapies of Huntington’s Chorea
Huntington’s Disease (HD) is an autosomal, dominantly inherited neurodegenerative disorder caused by an expansion of the CAG repeat in the huntingtin (HTT) gene. The disease generally manifests during mid-life and is clinically characterized by involuntary movements (chorea), psychiatric and behavioral symptoms, and cognitive decline. To this date, no cure or disease-modifying therapy exists. However, a wide variety of pharmacological therapies are used to improve quality of life.
  • 453
  • 23 May 2022
  • Page
  • of
  • 106
Video Production Service